Divi’s Laboratories Q4 Results: Divi’s Laboratories unveiled its fiscal Q4FY24 results on Saturday, May 25, revealing a significant surge in net profit. The numbers painted an impressive picture, with a remarkable 67.6% increase, soaring to ₹538 crore compared to ₹321 crore in the same period last fiscal year.
In the fourth quarter of FY24, Divi’s Laboratories witnessed a notable 18% uptick in revenue from operations, climbing to ₹2,303 crore from ₹1,951 crore in the corresponding period of the previous year. Additionally, the company’s board proposed a final dividend of 1,500%, equivalent to ₹30 per equity share with a face value of ₹2 each for the fiscal year ending March 31, 2024.
The proposed dividend is contingent upon the endorsement of the company’s shareholders. Divi’s Laboratories has scheduled its 34th annual general meeting (AGM) for August 12, 2024. Notably, the record date for dividend payment purposes is set for August 2, 2024. -Divi’s Laboratories Q4 Results
In the March quarter, Divi’s Labs witnessed a remarkable 50.1% surge in its earnings before interest, tax, depreciation, and amortization (EBITDA), reaching ₹731 crore from ₹487 crore year-on-year. This significant uptick reflects the company’s robust operational performance. Furthermore, the margin also showed a notable improvement, escalating to 32% compared to 25% in the corresponding period last year. This enhanced margin underscores Divi’s Laboratories’ efficient management of its operating expenses and resources.
Also Read: Aurobindo Pharma
At the close of trading on Friday, shares of Divi’s Laboratories concluded with a modest 0.30% increase, reaching ₹4,122.75 per share on the BSE.
Disclaimer: Stockeasynow provides stock market news for informational purposes only and should not be construed as investment advice. Readers are strongly encouraged to consult with a qualified financial advisor before making any investment decisions.
